Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Regeneron's suite deal

Back to the Future

Regeneron's suite deal

Having done a pair of non-exclusive deals for its VelocImmune antibody technology, Regeneron Pharmaceuticals Inc. decided there was a better way to monetize the platform and agreed to give sanofi-aventis Group options to all future therapeutic antibodies the biotech's VelociSuite produces. The partners hope to take two to three antibodies into the clinic each year over five years, which Regeneron will co-develop and have an

Read the full 700 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers